
BML, Inc.
4694.TJPXHealthcareMedical - Diagnostics & Research
最新資料
¥3,635
+¥10.00 · +0.28%
4694.T公司概覽
盤中時間採用JST。市場資料可能有所延遲。
公司概況
公司網站BML, Inc. is a Japanese corporation specializing in a comprehensive range of laboratory diagnostics and related services. The company conducts standard analyses such as biochemical and hematological screenings, in addition to advanced specialized tests including radioimmunoassay (RIA), cellular diagnostics, immunology, and DNA analysis. It also provides microbiological assessments for medical and pharmaceutical organizations, along with diagnostic services covering critical areas like oncology, infectious diseases, metabolic disorders (diabetes, hypertension), allergies, and genetic studies. To optimize laboratory operations, BML develops proprietary automation systems, Frontier and Symphony, designed to streamline processes from initial sample sorting and dispensing through to subsequent testing. The firm also supports medical information networking via electronic health records and offers preventative healthcare solutions. BML's extensive service portfolio includes food safety and environmental health. Its food division provides comprehensive hygiene control and processing support, encompassing contractual microbiological testing for raw ingredients, prepared, and processed foods. This extends to environmental hygiene assessments for food facilities and kitchens, general microorganism testing, and the evaluation of genetically modified organisms. Environmental services comprise drinking water and wastewater analysis, occupational health management (measuring airborne substances like ethylene oxide, formaldehyde, organic solvents, and dust), comprehensive indoor environmental monitoring (identifying contaminants and other variables), and biological dioxin surveillance. Moreover, BML performs analyses for residual agricultural chemicals, offers dental diagnostics for caries and periodontal diseases, provides consulting for pharmaceutical product approvals, conducts investigative analyses for drug manufacturers, and performs gene expression analysis, specifically identifying genes linked to infectious disease susceptibility. Founded in 1955, BML, Inc. is headquartered in Tokyo, Japan.
- 產業
- Medical - Diagnostics & Research
- 部門
- Healthcare
- 總部
- JP
- 執行長
- Kensuke Kondo
- 上市以來
- 2001年4月25日
- 僱員
- 4,612
市場位置
- 成交量
- 5.32萬
- 0.67× 平均值
- 平均成交量
- 7.95萬
- 日均成交量
- 市值
- 1362.53億 JPY
- 貝塔
- 0.24
- 市場參考 1
財務數據
財務快照
最近十二個月估值與收益率
- 企業價值
- 907.76億 JPY
- 本益比(TTM)
- 17.4×
- 股價淨值比(TTM)
- 1.07×
- 股價營收比(TTM)
- 0.9×
- EV/EBITDA
- 4.28×
- 盈餘收益率
- 5.03%
- 自由現金流收益率
- 7.77%
- 股息率
- 3.44%
獲利能力和效率
- 毛利率
- 32.57%
- 營業利益率
- 7.02%
- 淨利潤率
- 5.20%
- 股東權益報酬率
- 6.07%
- 資產報酬率
- 4.23%
- 投入資本報酬率
- 4.84%
財務健康
- 負債權益比
- 0.04×
- 流動比率
- 2.49×
- 奧特曼 Z 分數
- 4.03
- 皮奧特羅斯基 F 分數
- 5 共 9 個
財務報表
利潤率趨勢
獲利能力占已公布營收的百分比。
損益趨勢
營收
營業利益
淨利
| 項目(JPY) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 1502.62億 JPY | 1431.91億 JPY | 1379.64億 JPY | 1594.62億 JPY | 1860.67億 JPY |
| 銷貨成本 | 1015.72億 JPY | 973.29億 JPY | 923.35億 JPY | 980.16億 JPY | 991.16億 JPY |
| 毛利 | 486.9億 JPY | 458.62億 JPY | 456.29億 JPY | 614.46億 JPY | 869.51億 JPY |
| 研究與開發 | — | 2.6億 JPY | 2.75億 JPY | 2.71億 JPY | 3.02億 JPY |
| 銷售、一般及管理費用 | 382.67億 JPY | 362.37億 JPY | 361.86億 JPY | 372.38億 JPY | 377.59億 JPY |
| 營業費用 | 382.67億 JPY | 364.97億 JPY | 364.61億 JPY | 375.09億 JPY | 380.61億 JPY |
| 利息收入 | 1.06億 JPY | — | — | — | — |
| 利息支出 | 1.19億 JPY | 1.18億 JPY | 1.04億 JPY | 4000萬 JPY | 3600萬 JPY |
| 折舊和攤銷 | 91.21億 JPY | 77.16億 JPY | 67.91億 JPY | 63.48億 JPY | 58.92億 JPY |
| 營業利益 | 104.23億 JPY | 93.65億 JPY | 91.68億 JPY | 239.37億 JPY | 488.9億 JPY |
| 淨利 | 77.48億 JPY | 62.64億 JPY | 60.35億 JPY | 155.78億 JPY | 337.41億 JPY |
公司資料更新於 2026年8月24日。
財報歷史與展望
- EPS優於預期率
- 0%
- 優於預期0次、低於預期1次、符合預期0次
- 平均EPS意外幅度
- -15.64%
- 1 類似報告
- 最新每股收益結果
- 52.85
EPS:實際值與預估值
近期已公布業績
營收:實際值與預估值
近期已公布業績
持有4694.T的ETF
報告持有此股票曝險的交易所交易基金。
iShares Core TOPIX ETF1475.T2.57億0.01%2.89兆 JPY0.05%¥417.7-0.07%
Vanguard Total International Stock ETFVXUS680.79萬0.00%6462億 USD0.05%US$87.245-0.53%
Avantis International Small Cap Value ETFAVDV504.74萬0.03%202.42億 USD0.36%US$111.72-0.21%
Vanguard FTSE Developed Markets ETFVEA439.01萬0.00%3150億 USD0.03%US$73.145-0.37%
iShares Core MSCI EAFE ETFIEFA301.24萬0.00%1951.41億 USD0.07%US$100.7-0.15%
Vanguard FTSE All-World ex-US Small-Cap ETFVSS167.32萬0.01%136億 USD0.06%US$159.19-0.54%
iShares MSCI EAFE Small-Cap ETFSCZ151.19萬0.01%132.82億 USD0.40%US$86.58-0.02%
iShares Core MSCI Total International Stock ETFIXUS135萬0.00%609.08億 USD0.07%US$97.45-0.51%
iShares Core TOPIX ETF1475.T- 市場價值
- 2.57億
- 重量
- 0.01%
- AUM
- 2.89兆 JPY
- 費用率
- 0.05%
- 價格 / 1日
- ¥417.7-0.07%
Vanguard Total International Stock ETFVXUS- 市場價值
- 680.79萬
- 重量
- 0.00%
- AUM
- 6462億 USD
- 費用率
- 0.05%
- 價格 / 1日
- US$87.245-0.53%
Avantis International Small Cap Value ETFAVDV- 市場價值
- 504.74萬
- 重量
- 0.03%
- AUM
- 202.42億 USD
- 費用率
- 0.36%
- 價格 / 1日
- US$111.72-0.21%
Vanguard FTSE Developed Markets ETFVEA- 市場價值
- 439.01萬
- 重量
- 0.00%
- AUM
- 3150億 USD
- 費用率
- 0.03%
- 價格 / 1日
- US$73.145-0.37%
iShares Core MSCI EAFE ETFIEFA- 市場價值
- 301.24萬
- 重量
- 0.00%
- AUM
- 1951.41億 USD
- 費用率
- 0.07%
- 價格 / 1日
- US$100.7-0.15%
Vanguard FTSE All-World ex-US Small-Cap ETFVSS- 市場價值
- 167.32萬
- 重量
- 0.01%
- AUM
- 136億 USD
- 費用率
- 0.06%
- 價格 / 1日
- US$159.19-0.54%
iShares MSCI EAFE Small-Cap ETFSCZ- 市場價值
- 151.19萬
- 重量
- 0.01%
- AUM
- 132.82億 USD
- 費用率
- 0.40%
- 價格 / 1日
- US$86.58-0.02%
iShares Core MSCI Total International Stock ETFIXUS- 市場價值
- 135萬
- 重量
- 0.00%
- AUM
- 609.08億 USD
- 費用率
- 0.07%
- 價格 / 1日
- US$97.45-0.51%
繼續GoAI的研究
在 GoAI 中研究4694.Tresearch.disclaimer